China Nuclear Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

China Nuclear Imaging Market Trends and Insights

Increasing Oncology and Cardiology Disease Burden

China registered 4.82 million new cancer cases and 2.57 million deaths in 2022, reshaping demand for the China nuclear imaging market^{[1]Journal of Nuclear Medicine, “Nationwide Cancer Incidence 2024,” jnm.org} . Lung cancer alone contributed 1.06 million diagnoses, ensuring sustained PET/CT utilization for thoracic oncology. A 2024 trial showed that the nectin-4 tracer [68Ga]Ga-N188 matched 18F-FDG sensitivity while improving specificity for triple-negative breast cancer, signaling the diversification of tracers. Cardiology imaging remains nascent, yet autopsy data indicating 68.2% latent coronary disease in HFpEF patients position SPECT and PET perfusion protocols for growth. Clinical guidelines that endorse SPECT myocardial perfusion imaging as a first-line diagnosis, plus the emergence of 68Ga-FAPI for cardiac fibrosis, add incremental volume. Combined, these disease trends are expected to lift annual nuclear medicine exam penetration above the 0.28% baseline recorded in 2024.

National Healthcare Reform and Policy Support

The December 2024 Circular No. 53 cut clinical-trial review windows to 30 days in pilot provinces and shifted reimbursement assessment toward cost-effectiveness^{[2]Journal of Nuclear Medicine, “Circular No. 53 Policy Update,” jnm.org} . As a result, NMPA approvals for radiopharmaceuticals rose from ≈30 agents in 2022 to >40 by 2025. Fast-track licensing for Class IV user facilities also eased hospital entry barriers, although only 65 institutions held these permits in 2025. The Mid- and Long-Term Development Plan for Medical Isotopes (2021-2035) mandates nuclear medicine departments across all 2,749 Class 3 hospitals plus 2,000 additional sites, effectively doubling the addressable footprint for the China nuclear imaging market. While fragmented, reimbursement now accommodates cost-utility metrics, encouraging provinces to pilot coverage for expensive modalities such as total-body PET.

Demographic Aging and Rising Healthcare Expenditure

Adults aged≥65 years will account for 27% of China’s population by 2040, up from 14% in 2024, intensifying demand for neurodegenerative imaging [JNM.ORG]. A 1,073-patient amyloid-PET cohort at Huashan Hospital altered diagnoses in 19.3% of Alzheimer’s workups, demonstrating clinical utility. Total-body PET enables dual-tracer scans—11C-CFT and 18F-FDG—in 600 seconds, doubling daily throughput and aligning with elderly patients’ tolerance limits. Despite 0.305 PET scanners per million residents in 2024, versus 7.2 in the United States, provincial budgets earmark incremental capex for PET/CT as part of aging-care initiatives. These demographic and fiscal shifts add 1.5 percentage points to the forecast CAGR of the China nuclear imaging market.

Expansion of Domestic Radioisotope Production Capacity

CNNC launched Lu-177 lines at Qinshan in June 2025, with an annual output of≥10,000 curies, slashing import dependence for 177Lu-DOTATATE and 177Lu-PSMA treatments [JNM.ORG]. China Isotope & Radiation Corporation began building a Mo-99/Tc-99m reactor in January 2024, targeting 100,000 curies by 2027, sufficient for national SPECT demand. First-in-China production of Y-90 glass microspheres and C-14 in 2025 and 2024, respectively, diversifies tracer supply, while Eckert & Ziegler’s Ac-225 license agreement moves alpha-therapy precursors in-country. Improved isotope self-reliance stabilizes input costs, explains the 2.3 percentage-point CAGR uplift, and pivots the China nuclear imaging market toward consumables-led revenue.

High Capital Expenditure and Reimbursement Constraints

Total-body PET units cost RMB 70-100 million (USD 9.8-14 million), roughly triple the cost of conventional PET/CT, straining hospital capex cycles when provincial reimbursement lists still price scans at RMB 6,000-9,000. Volume-based purchasing further squeezed 18F-FDG tariffs by 33% between 2022 and 2024, stretching equipment payback to eight-plus years. Catastrophic out-of-pocket ceilings of RMB 400,000-450,000 discourage multi-cycle 177Lu therapies, muting consumable pull-through. Independent imaging centers navigate multi-agency licensing that may take 18 months, delaying revenue realization and trimming the CAGR of the China nuclear imaging market by 1.4 percentage points.

Logistical Challenges of Short-Half-Life Isotopes

China’s 148 cyclotrons in 2024 clustered in the east, leaving Xinjiang and Qinghai reliant on air freight that adds RMB 2,000-5,000 per 18F-FDG dose. Only 10 sites run 82Rb generators versus >200 in the U.S., curbing cardiac PET expansion. Technetium shortages following 2024 European reactor outages forced appointment rescheduling, exposing supply fragility until China Isotope’s Mo-99 reactor comes online in 2027. These logistical frictions shave 0.9 percentage points off the China nuclear imaging market CAGR.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Domestic Isotope Push Reshapes Revenue Mix

Equipment generated 64.23% of the China nuclear imaging market share in 2025, buoyed by ≈20 total-body PET installations and photon-counting CT launches. However, radioisotopes are on track for an 11.54% CAGR through 2031 as Qinshan’s Lu-177 and future Mo-99 reactors underpin supply. Consequently, the China nuclear imaging market size for consumables is expected to surpass equipment sales by 2029. Competitive dynamics favor state-owned CNNC and growing private players that secure long-term supply contracts with academic centers.

The projected shift toward a consumables-driven model supports recurring revenue streams, stabilizing profitability despite price compression in scanners. Y-90 glass microsphere rollouts and Ac-225 partnerships add high-margin therapy isotopes that deepen the moat for early movers. United Imaging’s strategy now pairs hardware with tracer-agnostic service bundles, a logical hedge as the China nuclear imaging market transitions to isotope-led growth.

By Application: Oncology Dominance Masks Neurology’s Velocity

Oncology contributed 41.56% of 2025 revenue, underpinned by lung-cancer prevalence and November 2025 approval of Pluvicto. Novel PET tracers such as nectin-4 and CLDN18.2 are widening the diagnostic funnel, and FAPI theranostic pairs promise procedure upsell. Even so, neurology will log the highest CAGR at 11.67%, supported by 600-second total-body PET dual-tracer protocols. By 2031, neurology’s share of the China nuclear imaging market size could advance 3-4 percentage points, fueled by tau-PET approvals and reimbursement expansion.

Cardiology remains a low-volume niche today, but guideline revisions and 68Ga-FAPI’s superior uptake in fibrosis position it for catch-up growth. Thyroid and infection imaging stay steady yet undifferentiated, offering limited incremental upside. Collectively, application diversification cushions the China nuclear imaging market from oncology reimbursement risk.

By End User: Imaging Centers Exploit Tier-2 White Space

Hospitals accounted for 65.43% of 2025 revenue, reflecting their lock on Class IV tracer licenses and established radiopharmacies. Diagnostic imaging centers, however, are expanding at 10.54% CAGR as private operators rush into tier-2 locales where nuclear medicine coverage remains under 35%. This segment’s agility—free from multispecialty hospital bureaucracy—allows targeted high-margin oncology scans that lift average revenue per unit.

Mid-term policy pledges to equip every Class 3 hospital plus 2,000 additional facilities by 2035 equate to 3,000-4,000 new scanners, but staffing and isotope supply will dictate the pace. Imaging-center growth hedges against hospital procurement lulls, ensuring the China nuclear imaging market retains demand momentum across diverse care settings.

Regulatory Landscape

China's nuclear imaging market operates under the National Medical Products Administration (NMPA) framework for medical devices and radiopharmaceuticals, with heightened focus on higher-risk modalities and manufacturing quality systems. In October 2025, NMPA Announcement No. 63 flagged high-end medical imaging equipment as a priority area under an optimized, whole life-cycle regulatory approach, tightening expectations around design controls, post-market surveillance, and traceability while retaining faster pathways for innovation.

A near-term compliance milestone is the revised Good Manufacturing Practice (GMP) for Medical Devices released by the NMPA in November 2025, which takes effect on November 1, 2026. In parallel, policy direction from the State Council (GBF No. 53) reinforces localization of high-end medical equipment and streamlines review considerations for transferring overseas medical-device production into domestic Chinese enterprises, shaping investment decisions for imaging OEMs and related suppliers.

Value Chain Analysis

China's nuclear imaging value chain spans isotope production (reactor- and cyclotron-based), radiopharmaceutical synthesis and quality control, distribution and cold-chain logistics, imaging equipment manufacturing and service, and clinical delivery in hospitals and imaging centers. Upstream supply is increasingly anchored by domestic isotope manufacturing, with CNNC shipping lutetium-177 from Qinshan beginning in June 2025, reducing dependence on imported therapy isotopes and improving availability for theranostics-driven protocols.

Midstream and downstream, regulation and standardization are tightening quality gates while expanding testing capacity. The NMPA issued Procedures for Assessment of Drug Control Institutions for technetium-labeled and positron radioactive pharmaceuticals (No. 21 of 2024) to broaden qualified testing institutions, and in August 2025 the Standardization Administration of China released GB/T 20013.2-2025 for routine testing of SPECT and gamma camera imaging equipment, updating the 2005 version. These moves reinforce a more integrated workflow among device OEMs, radiopharm producers, and licensed nuclear medicine departments around GMP, routine performance testing, and reliable tracer supply.

Market Opportunities and Future Outlook

White space remains sizable in licensed capacity and site coverage, creating opportunities for equipment vendors, radiopharmaceutical manufacturers, and service providers to expand beyond tier-1 city centers. As of 2024, China had 588 nuclear medicine departments with Type II licenses, 326 with Type III licenses, and 69 with Type IV licenses, indicating a constrained base for investigational tracer synthesis relative to national ambitions. Government programs support this expansion pathway, including the Mid- and Long-Term Development Plan for Medical Isotopes (2021-2035), which directs nuclear medicine department expansion to every county by 2035, and the Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024-2026), which calls out next-generation high-end nuclear medical imaging equipment and radiopharmaceutical innovation.

Foshan Radiopharmacy (a subsidiary of Beijing Jiluntai) received NMPA approval in April 2026 for technetium 99mTc-3PRGD2, positioned as China's first domestically developed Class 1 innovative nuclear medicine drug for SPECT/CT tumor imaging. Alongside the November 2025 NMPA approval of Novartis radioligand therapy Pluvicto, these approvals broaden the clinical toolkit and strengthen the business case for hospital radiopharmacies, tracer distribution networks, and imaging-center buildouts that can operationalize both diagnostic SPECT/PET growth and theranostics-linked workflows.